We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck announced a wide-ranging restructuring plan late last month centered on a major overhaul of its drug-making operations, including a global rollout of lean manufacturing principles, but industry analysts said the move may not be enough to bolster the company, as Merck is as much as 10 years behind the rest of the industry in revamping its operations.
Barr Pharmaceuticals has finalized an agreement with Organon and Savient Pharmaceuticals to acquire the exclusive rights to the oral contraceptive Mircette.
The European Commission has approved Teva Pharmaceutical's bid to buy U.S. drug firm Ivax for $7.4 billion, bringing Teva one step closer to reclaiming its title as the world's largest generic drugmaker.
Merck intends to shutter manufacturing facilities in Georgia, Pennsylvania and Canada as part of its sweeping corporate restructuring announced earlier this week.
Merck is moving forward with a major restructuring of its manufacturing division in an effort to boost profits, but industry analysts say the move may not be enough to bolster the company, as Merck is as much as 10 years behind the rest of the industry in revamping its operations.
Merck intends to shutter manufacturing facilities in Georgia, Pennsylvania and Canada as part of its sweeping corporate restructuring announced earlier this week.
The European Commission has approved Teva Pharmaceutical's bid to buy U.S. drug firm Ivax for $7.4 billion, bringing Teva one step closer to reclaiming its title as the world's largest generic drugmaker.
U.S.-based generic firms Mylan Laboratories and Barr Laboratories have a leg up in the race to win a sublicense for Roche's highly sought-after antiviral Tamiflu, according to a recent Banc of America Securities report.
The European Commission has approved Teva Pharmaceutical’s bid to buy U.S. drug firm Ivax for $7.4 billion, bringing Teva one step closer to reclaiming its title as the world’s largest generic drugmaker.
Pharmaceutical firm Allergan, maker of the antiwrinkle treatment Botox, has offered roughly $3.2 billion to buy cosmetic device manufacturer Inamed -- a proposal that comes as Inamed already is in merger talks with dermatology products firm Medicis Pharmaceutical.